We formulated and evaluated proliposomal gel of relatively low bioavailable drug lisinopril dihydrate (LDH) for transdermal delivery. Several proliposomal gel formulations of lisinopril dihydrate were prepared by modified coacervation phase separation method and examined for formation of liposomes by optical microscope and characterized by transmission electron microscopy. The formulations were evaluated for size, zeta potential, entrapment efficiency,_x000D_ rheological behavior, ex vivo drug permeation, skin irritation and stability. Differential scanning calorimetry (DSC) and Fourier transform infrared (FTIR) studies were performed to understand the phase transition behavior and mechanism for skin permeation, respectively. The microscopic examination revealed the formation of liposomes from proliposomal gel, and the size of the vesicles was found to be in the range of 385 nm to 635 nm. Entrapment efficiency was high for the formulation containing greater amounts of phosphatidylcholine. The DSC studies indicated the amorphous form of LDH in proliposomal gel formulation. Ex vivo permeation studies revealed sustained permeation of drug from proliposomal gels studied. The stability studies reveal that the proliposomal formulations are more stable when stored at refrigeration temperature (4 oC). In conclusion, proliposomal gels offer potential and prove to be efficient carriers for improved and sustained transdermal delivery of lisinopril dihydrate.

Lisinopril Dihydrate Proliposomes Microscopy Transdermal Permeability

Lancaster SG, Todd PA, Drugs., 35, 646 (1988)
Marc H, Angiotensin converting enzyme inhibitors, angiotensin and calcium channel blockers, In: A.D. Williams, L. L. Thamas Eds., Foye’s principles of medicinal chemistry, 5th Ed., M. D. Baltimore: Lippincott Williams and Wilkins (2002)
Gurrapu A, Jukanti R, Bobbala SR, Kanuganti S, Jeevana JB, Adv. Powder Technol., 23(5), 583 (2012)
Vaibhav D, Dinesh M, Jain NK, Eur. J. Pharm. Biopharm., 67, 398 (2007)
Calder PC, Jensen GL, Koletzko BV, Singer P, Wanten GJ, Intensive Care Med., 36, 735 (2010)
Tamilvanan S, Benita S, Eur. J. Pharm. Biopharm., 58, 357 (2004)
Prausnitz MR, Mitragotri S, Langer R, Nat. Rev. Drug Discov., 3, 115 (2004)
Wu PC, Huang YB, Chang JJF, Chang JS, Tsai YH, Int. J. Pharm., 209, 87 (2000)
Rajesh K, Gupta RB, Betageri GV, Drug Deliv., 8, 25 (2001)
Payne NI, Timmis P, Ambrose CV, Warel MD, J. Pharm.Sci., 75, 325 (1986)
Betageri GV, US Patent, 6, 249 (2005)
Touitou E, Junginger HE, Weiner ND, Nagai T, Mezei M, J. Pharm. Sci., 83, 1189 (1994)
Schreier H, Bouwstra J, J. Control Release., 30, 1 (1994)
Mokhtar M, Sammour OA, Hammada MA, Megrab NA, Int. J. Pharm., 361, 104 (2008)
Udupa N, Chandraprakash KS, Umadevi P, Pillai GK, Drug Dev. Ind. Pharm., 19, 1331 (1993)
Deepika A, Indu PK, Int. J. Pharm., 290, 155 (2005)
Vora B, Khopade AJ, Jain NK, J. Control Release., 54, 149 (1998)
Sagar DM, Vandana BP, Int. J. Pharm., 363, 132 (2008)
Zhao K, Singh J, J. Control Release., 62, 359 (1999)
Sunil TN, Ramesh P, J. Control Release., 95, 367 (2004)
Azarbayjani AF, En Hui Tan EH, Chan YW, Chan SY, Biol. Pharm. Bull., 32, 1453 (2009)
Joshi MD, Patravale VB, Drug Dev. Ind. Pharm., 32, 911 (2006)
Jukanti R, Sheela S, Bandari S, Veerareddy PR, J. Pharm. Sci., 100, 3208 (2011)
Varshosaz J, Pardakbty A, Baharanchi SMH, Drug Deliv., 12, 75 (2005)
EI-Ridy MS, Khalil RM, Moustafa DM, Mohamed M, Monem AS, Drug Dev. Ind. Pharm., 23, 771 (1997)
Hiremath PS, Soppimath KS, Betageri GV, Int. J. Pharm., 380, 96 (2009)
Hwang BY, Jung BH, Chung SJ, Lee MH, Shim CK, J. Control Release., 49, 177 (1997)